{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-117245","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.507224+00:00","generated_at":"2026-05-21T23:30:23.600370+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CytomX Q1 revenue $50.9M; CX-2051 Phase 1 shows 28% ORR in advanced CRC","bullets":["Q1 revenue $50.9M (up from $41.5M); operating expense $28.3M; cash $79.9M.","CX-2051 Phase 1: 28% ORR (5/18 confirmed PRs), 94% DCR, median PFS 5.8 months in advanced CRC.","Dose expansions started at 7.2, 8.6, 10 mg/kg Q3W; Phase 2 planned 1H 2026.","Astellas milestone $5M; cash runway into Q2 2026.","CX-801 Phase 1a data in melanoma expected 2H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-117245","json":"https://secwatch.observer/filing/0001193125-25-117245.json","markdown":"https://secwatch.observer/filing/0001193125-25-117245.md","text":"https://secwatch.observer/filing/0001193125-25-117245.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000119312525117245/0001193125-25-117245-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000119312525117245/d23036d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:30:23.600370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}